A Patient’s Guide to Clinical Trials
En Español | En Français
NIH Clinical Research Trials and You
Guidance regarding HIV anti-retroviral treatment in developing countries
Policy on Research Involving Human Subjects
Current therapy of eosinophilic esophagitis and eosinophilic gastroenteritis is limited to highly restrictive elimination diets or off-label use of corticosteroids. This investigational study will examine the safety and effectiveness of low-dose sirolimus in reducing high blood and tissue eosinophil counts in patients with eosinophil-associated gastrointestinal disorders. Sirolimus is FDA-approved for use in kidney transplant recipients to prevent organ rejection.
You may be eligible if you:
Participants will take sirolimus daily for 2 months and will travel to the NIH 5 times over 5 months for check-ups and blood draws; some participants may require 1-2 additional visits over 1-2 months. Participants will have an upper GI endoscopy at the beginning and end of the study.
The study is being conducted at the Warren Grant Magnuson Clinical Center at the National Institutes of Health (NIH) in Bethesda, Maryland. The NIH campus is accessible by car and public transportation.
There is no charge to participate in this research study. All study-related medical care and procedures are provided free of charge.
There is no compensation for study participation. Transportation and other expenses may be covered.
To see if you may qualify or for more information contact:
Patient Recruitment and Public Liaison Office, NIH Clinical Center
Toll Free: 1-800-411-1222 (reference study# 13-I-0094)
TTY: 1-866-411-1010 Se habla español.
Office hours: 8 a.m.-3:30 p.m. EST
To learn more about this study of sirolimus in treating eosinophil-associated gastrointestinal disorders (trial ID: NCT01814059), visit ClinicalTrials.gov.
Last Updated May 29, 2013
Last Reviewed May 29, 2013